
|Videos|July 23, 2021
First Vyluma product tackles pediatric myopia
Advertisement
Dive deep into Vyluma’s investigational atropine therapy. Navneet Puri, PhD, the company’s founder, chairman, and CEO, explains details of the clinical trials.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Ortho-k: More than meets the eye to control myopia progression
2
Drs Kaleb Abbott, Andrew Pucker suggest changing "artificial tear" terminology
3
Crafting your own eyewear brand: Streamlining the private label process
4
ONL Therapeutics reports positive phase 1b data for xelafaslatide in GA
5












































.png)


